brucellosis. Brucellosis
Conditions
Interventions
Intervention 1: Intervention group: Doxycycline treatment 100 mg q 12h + rifampin 900-1200 mg / dayIn this group, the patient is instructed to take two rifampin 300 mg capsules every morning on an emp
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: Isolation of Brucella in culture of blood or bone marrow or other body fluids Positive Brucella PCR test in blood and / or body fluids or tissue samples Wright title equal to or greater than 160/1 The title of Combs Wright is at least two levels higher than Wright
Exclusion criteria
Exclusion criteria: Age less than 14 years- Intrinsic or acquired immunodeficiency Simultaneous with advanced or chronic heart, lung, liver and kidney diseases Pregnancy- Taking oral contraceptives Consumption of phenytoin History of receiving anti-brucellosis treatment in a recent month for more than a week Infection with local forms of malaria, endocarditis, spondylitis, meningitis, etc. Taking antibiotics more than 7 days before the visit History of allergy to doxycycline or rifampin General malaise so that the patient is not able to take medication orally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to treatment. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Patients are divided into the following three groups in terms of response to treatment:1- Complete recovery: Complete recovery is considered when the symptoms disappear with treatment and by the end of the follow-up dose, the symptoms do not return and clinical signs are not found in favor of brucellosis.Relapse: It is when the symptoms have disappeared with treatment, but in the one-year follow-up period after the end of treatment, the symptoms have returned.3 - persistence of infection or treatment failure: is when the signs and symptoms of the disease at the end of treatment are still present. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Presence or absence of side effects.;Wright laboratory test. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Based on the results of the Wright laboratory test.;Coombs test. Timepoint: The second, fourth, sixth and eighth weeks after starting treatment and up to three months after treatment. Method of measurement: Based on the results of the Coombs laboratory test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Salehi
Tehran University of Medical Sciences
Outcome results
None listed